Speakers

Speaker line-up

Marc Gitzinger, CEO, BioVersys AG, CH

Kevin Outterson, Executive Director, CARB-X, US

Jean-Pierre Paccaud, Director of Business Development and Corporate Strategy, GARDP

Erin Duffy, Chief of Research & Development, CARB-X

Peter Jackson, Executive Director, AMR Centre Ltd, UK

Aleks Engel, Partner Novo Seeds and Director, Novo Holdings, REPAIR Impact Fund, DK

Felicitas Riedl, Head of Life Science Division, European Investment Bank

Peter Beyer, Senior Advisor Department of Essential Medicines & Health Products, World Health Organization

Till Bachmann, Deputy Head of Infection Medicine & Personal Chair of Molecular Diagnostics and Infection, University of Edinburgh

Tom Monroe, CEO, Vaxxilon AG

Javad Aman, President and CSO, Intergrated BioTherapeutics Inc

Alexander Belcredi, CEO, Phagomed

Oswald Lockhoff, CEO, Sidanis Pharma

Philippe Cleuziat, Innovation Program Senior Director, bioMérieux & Project Lead IMI ValueDX

Emily Adams, Diagnostic Lead of the Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine (LSTM)

Sarah Paulin, Technical Officer of Antimicrobial Resistance (AMR) and Innovation, Access and Use, World Health Organization (WHO)

Katerina Galluzzo, Technical Manager, Strategy Team, UNITAID

Heiman Wertheim, Head of Clinical Microbiology Department, Radboud University, NL

Seamus O’Brien, R&D Director, GARDP, CH

Christoph Dehio, Biozentrum, The Center of Molecular Sciences, University of Basel, CH

Gokhan Batur, Chief Commercial Officer, Polyphor, CH

Sumathi Nambiar, Director, Division of Anti-Infective Products (DAIP), Office of Antimicrobial Products, CDER, FDA, US

William Hope, University of Liverpool, Head of Centre of Excellence in Infectious Diseases Research (CEIDR), UK

Jonathan Butcher, Head of Business Development & Alliance Management, BioVersys, CH

Pierre Tangermann, CEO, Periotrap, DE

Andreas Bastian, CEO, AGiLebiotics

Shampa Das, Centre of Excellence in Infectious Diseases Research (CEIDR), UK

Paul Finn, CEO, Oxford Drug Discovery, UK

Philipp Knechtle, Director Microbiology, Allecra

Laurenz Kellenberger, CSO, Basilea Pharmaceutica, CH

Karen Gallant, Global R&D Director, CARB-X, US

Fiona Marston, Director, Centre of Excellence in Infectious Diseases Research (CEIDR), UK

Achim Plum, Managing Director, Ares Genetics

Daniel Berman, Lead, Nesta Challenges & Longitude Prize

Kwangmin Son, CEO, PHAST Inc.

Lasse Görlitz, Director of Brand & Communication, grit42

Cesar de la Fuente, Presidential Assistant Professor, University of Pennsylvania, US

Dirk Bumann, Biozentrum, The Center for Moleculare Life Sciences, University of Basel

Samareh Azeredo da Silveira Lajaunias, Managing Director, Combioxin SA, CH

Stefan Hagel, Principal Investigator, Center for Infectious Diseases and Infection Control, Jena University Hospital, DE

Elmar Nimmesgern, Secretariat Lead, Global AMR R&D Hub, DE

Colm Leonhard, Clinical Adviser/Consultant, NICE, UK

Philippe Cleuziat, Innovation Program Senior Director, bioMérieux/VALUE-Dx, FR

Klaus Hellmann, Managing Director, Klivofet AG, DE

Peter Warn, SVP, Ant-iinfective Discovery, Evotec

Richard Knight, Director & Co-founder, ApconiX

Aleksandar Danilovski, CSO and Senior Vice President Global R&D and Regulatory Affairs, Xellia

Irene Wütherich, CEO, SpheroBiotics, CH

Thomas Hesterkamp, Myxobiotics, GER

David Barros-Aguirre, Head of Tuberculosis Discovery Programme, GlaxoSmithKline, ES

Florian von Groote-Bidlingmaier, Global Head Executive Vice President – Head of Global Health and Clinical Development Infectious Diseases, Evotec, FR 

Florian Kloss, Head, Hans Knöll Institute (HKI), GER & Michael Hoelscher, Network Coordinator, Ludwig-Maximilians-University Munich (LMU), GER

Robert Skov, Scientific Director, ICARS, DK

Jonathan Rushton, Professor of Animal Health and Food Systems Economics, University of Liverpool, CEIDR, UK

Timo Minssen, Founder and Managing Director, Center for Advanced Studies in Biomedical Innovation Law (CeBIL), DK

Till Schäberle, Professor, Department of Insect Biotechnology, University of Gießen & German Center of Infectious Diseases (DZIF), GER 

Timothy Schulz-Utermoehl, Co-founder and Director, Pedanius Therapeutics, UK

Ken Bradley, Global Head Infectious Disease Discovery, Roche

Sally Ellis, Project Leader of the Neonatal Sepsis, GARDP

Viviana Munoz Tellez, Programme Coordinator, Health, IP and Biodiversity (HIPB), South Centre, CH​​